Thermosensitive Hydrogels For Sustained Delivery Of Anti-Inflammatory Drugs: Recent Advances, Challenges, And Future Perspectives
www.ijsrtjournal.com
Aug. 15, 2026, 4:05 a.m.
Chronic inflammation underlies numerous diseases including inflammatory bowel disease, rheumatoid arthritis, and asthma, typically managed with NSAIDs, corticosteroids, or DMARDs. However, conventional drug delivery suffers from poor site specificity, high systemic clearance, and frequent dosing requirements. Thermosensitive hydrogels represent a promising alternative, leveraging their high water content, biocompatibility, and capacity to encapsulate diverse therapeutics. These injectable systems undergo reversible sol-to-gel transformation at physiological temperature, forming depot matrices that enable localized, controlled drug release with improved patient compliance. Common materials include poloxamers, poly(N-isopropylacrylamide), chitosan, methylcellulose, and poly(ethylene glycol)-based copolymers, offering tunable gelation temperatures, biodegradability, and mechanical properties. These systems show significant promise for delivering anti-inflammatory agents via topical, intra-articular, ocular, transdermal, and injectable routes. Despite encouraging preclinical results, clinical translation remains hindered by challenges including poor mechanical stability, premature drug release, limited drug loading capacity for hydrophobic compounds, variable drug-gelation interactions, and sterilization and scale-up difficulties.